AstraZeneca shares leap with FDA set to review drug to treat breast cancer
1. AstraZeneca shares rose 7% following FDA's review announcement for Enhertu. 2. The FDA ruling for Enhertu is expected by May 18, 2026. 3. Enhertu showed significant improvement in high-risk early-stage breast cancer patients. 4. Sales of Enhertu reached $2.29 billion in the first half of the year. 5. AstraZeneca's shares also benefited from the Pfizer deal affecting the sector.